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Abstract. The Board of Pharmaceutical Sciences (BPS) of the International Pharmaceutical Federation
(FIP) has developed a view on the future of pharmaceutical sciences in 2020. This followed an
international conference with invited participants from various ﬁelds (academicians, scientists, regulators,
industrialists, venture capitalists) who shared their views on the forces that might determine how the
pharmaceutical sciences will look in 2020. The commentary here provides a summary of major research
activities that will drive drug discovery and development, enabling technologies for pharmaceutical
sciences, paradigm shifts in drug discovery, development and regulations, and changes in education to
meet the demands of academia, industry and regulatory institutions for pharmaceutical sciences in 2020.
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INTRODUCTION
In 2007, the Board of Pharmaceutical Sciences (BPS) of the
International Pharmaceutical Federation (FIP) launched a proc-
ess to develop a view on The Pharmaceutical Sciences in 2020. In
projecting forward, the Board posed four questions:
& What major research activities will drive drug discov-
ery and development?
& What will the enabling technologies be?
& What paradigm shifts will there be in drug discovery,
development, regulation and usage?
& How will changes in education meet the demands of
academia, industry and regulatory institutions?
These issues were discussed at an international conference
convened in Amsterdam in 2008 (1) with participants from a
broad spectrum of backgrounds (scientists, venture capitalists,
industrialists, regulators—see Electronic supplementary material,
list of conference participants). A series of plenary lectures
provided a basis for further discussion within small groups, each
chaired by an experienced pharmaceutical scientist. While
considerations of what is practical and affordable were acknowl-
edged, the participants were encouraged to be wide-ranging and
bold in their projections. The results of the deliberations of the
groups were presented by the chairs in open forum on the ﬁnal
day of the conference and are summarised here.
MAJOR RESEARCH ACTIVITIES THAT WILL DRIVE
DRUG DISCOVERY AND DEVELOPMENT
Consistent with its breadth, pharmaceutical science will
continue to feed off research and innovation in many adjacent
ﬁelds, especially in relation to target identiﬁcation, systems
biology, in vitro/in silico prediction of pharmacokinetics,
pharmacodynamics and toxicology, bioengineering/materials
science/nanotechnology, personalized medicine, information
technology/bioinformatics and research at interfaces.
Approaches to identifying new targets based on the use
of disease models, genomic information and RNA-DNA-
based approaches will mature. More attention will be given to
polypharmacology, the principle of targeting multiple sites of
action at the same time, active immunotherapy and targets for
neglected and emerging diseases.
The trend towards moving away from a reductionist to a
more holistic approach in understanding pharmacology is likely
to continue with the belated realisation that “omics” as such
are not the solution to everything but should be incorporated
into a fuller mechanistic and quantitative appreciation of
biological systems. This will fuel a re-emphasis on under-
standing function, extending into the renaissance of clinical
pharmacology within translational research.
Signiﬁcant advances that have been made in the
mechanistic prediction of pharmacokinetic behaviour based
on the use of human in vitro systems and computer model-
ling will be extended into pharmacodynamics and, partic-
ularly, toxicology (driven by the pressure to reduce animal
experimentation).
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The interface between formulation science and engineer-
ing will continue to be at the frontier of new product
development, with applications extending ever further into
targeted delivery and monitoring—although the cost-beneﬁt
of such developments is difﬁcult to anticipate.
While the promise of personalised medicine has been
elusive, it is anticipated that with an increasing recognition
that environmental, behavioural and social inﬂuences as well
as genetics are important components of drug response, there
will be a more realistic, evidence-based application of
pharmacogenetics in the future, supported by economic
analysis of its value.
Alongside developments in computer technology, there
will be an increasing need to make better use of latent and
forgotten information and literature. This will facilitate not
only basic research in linking up pieces of information, but
will also provide the broad information base required to
deliver personalised healthcare to patients.
In as much as innovation ﬂourishes where research
cultures meet, the boundaries between the three Ds (diag-
nostics, drugs and devices) will blur.
ENABLING TECHNOLOGIES
FOR PHARMACEUTICAL SCIENCES IN 2020
In order to deliver the research outlined above, it is
envisaged that signiﬁcant developments will occur in key
technologies.
Ultrafast computing will be facilitated by a move from
silicon-based to other forms of microprocessor technology
(biological and photon-based systems). Future software will
rapidly make it possible to visualise increasingly complex,
data-rich, dynamic systems, allowing realistic, real-time pre-
dictions at molecular, cell, organ, whole body and societal
levels, as well as the creation of increasingly sophisticated
virtual realities. Furthermore, cheap, ultrafast access to and
transmission of huge amounts of information and databases
will be possible. These and other developments will continue
to transform personal interactions and education.
Stem cells and other techniques in regenerative medicine
have the potential to radically alter the treatment of major
diseases, such as cancer and neurodegenerative disorders. If
they deliver within the next decade, they could lead both to a
signiﬁcant decrease in the use of some classes of drugs as well
as the opening of new avenues for the use of pharmaceuticals.
Developments in this area are likely to have a major impact
on disease modelling and drug screening.
Increases in the ability to follow levels of drugs and
biomarkers by non-invasive imaging in all parts of the body
and even within single cells will add huge value to the
application of pharmacokinetic and pharmacodynamic mod-
elling, toxicological assessment and translational medicine.
Engineering technologies that allow miniaturisation will
emerge increasingly from the realms of science ﬁction into
reality with the exciting potential for the application of
nanotechnology (nanobots/chips/smart membranes/nano-
shells) in drug delivery and the pervasive, real-time monitor-
ing of compliance/adherence to treatment (pharmionics),
diagnosis and drug safety/efﬁcacy.
Economic considerations will continue to drive the
development of increasingly sophisticated robotic systems,
particularly in the areas of iterative organic synthesis,
compound screening procedures and oversight of manufac-
turing processes.
Enhanced and pervasive information technology for
sharing knowledge will enable much more efﬁcient transfer
and sharing of pre-competitive data and information. It is
likely that a growing “non-silo R & D mentality” will emerge,
resulting in large, multidisciplinary, web-based research infor-
mation networks aiming to minimise duplication and, thereby,
facilitate drug design and development (e.g. caBIG—cancer
Biomedical Informatics Grid; https://cabig.nci.nih.gov). The
semantic web will extend the process of automated information
gathering to intelligent sorting and interpretation.
PARADIGM SHIFTS IN DRUG DISCOVERY,
DEVELOPMENT AND REGULATION
IN PHARMACEUTICAL SCIENCES BY 2020
The blockbuster business model for drug discovery and
development is unlikely to be sustainable as increased R & D
costs are coupled with a disproportionately lower ﬁnancial
yield from new pharmaceutical products. In the future, the
arsenal of new drugs is expected to comprise a larger number
of high value, niche agents tailored more closely to individual
patient needs and each associated with smaller sales.
While Big Pharma will continue to hold a dominant
position in clinical drug development and marketing, aca-
demia and SMEs (Small-to-Medium Enterprises) are likely to
have more prominent roles in discovery and, along with
CROs (Contract Research Organisations), in pre-clinical
development and the establishment of generic technology
platforms. Public-private partnerships will be an established
model bridging the gap between industrial and academic
research. Pharma will realign from a product to a healthcare
management focus with greater integration of diagnostics,
drugs and devices and more emphasis on preventative and
lifestyle medicine. The diagnostics-drug-device paradigm is
illustrated by the combination of cholesterol monitoring—use
of statins and insertion of drug-eluting stents.
As a result of healthcare cost containment policies and
other related trends, R & D plans will incorporate third-party
willingness to pay, and, thereby, pharmacoeconomic assess-
ment will be further incorporated into medicine regulation.
This may lead to the wider implementation of new models,
such as the “no cure—no pay” or “payment for outcomes”
approaches, providing that agreement can be reached on
appropriate end-points. It is not yet clear what impact this
type of model will have on incremental innovation
Incentives for developing treatments for neglected dis-
eases will be increased by the establishment of public-private-
development partnerships involving collaboration between
companies, governments, academia and charitable and non-
proﬁt organisations
Economic constraints on the development of medicines
will tend to drive a more holistic and socially oriented view of
R & D. Not only will this be reﬂected in the development of
new remedies, but there will be increasing recognition of the
need to provide better education of prescribers and patients
in the safe and effective use of existing drugs in an attempt to
reduce the signiﬁcant burden on health services associated
with inappropriate drug and dosage selection.
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Successful development and registration of biologicals
has begun to outpace that of small molecules, especially in the
area of oncology. However, considerable investment in the
discovery of products based on small molecules will continue,
especially in areas such as CNS pharmacology. Biosimilars
will become increasingly important with respect to pharma-
ceutical development and usage.
An aging population will lead to an increased demand
for health care along with more complex treatment and the
use of polypharmacy. Markets for pharmaceuticals will
expand with the projected emergence of middle classes in
countries such as India and China. In addition, the growth of
drug discovery and development is likely to increase in these
areas as multinational companies seek to increase the global-
isation of their operations and opportunities.
Universal access to medicines will be a crucial issue in
the context of the existing system of protection of intellectual
property rights. The WHO global strategy and plan of action
on public health, innovation and intellectual property may
have a dramatic impact on the global availability of medicines
and drivers of innovation.
The increasing regulatory burden has contributed to
prolonged drug development times and a decline in the
marketing of innovative new drugs. This will require more
creative thinking on the part of industry and regulatory
authorities to reward innovation while maintaining safety
standards for therapies as demanded by society.
Barriers between the different traditional phases of drug
discovery and development will blur (e.g. post-marketing
surveillance will be integrated with Phase III studies), and
there will be a need for more advanced pharmacovigilance
systems that interrogate efﬁcacy as well as safety.
Regulatory bodies will be asked to increase the trans-
parency of the decision-making process. They may develop
and implement ideas for shorter pre-market and longer post-
market periods of new drug evaluation in selected therapeutic
areas. To this end, new ways of managing uncertainty and
better methods to detect potential risk earlier will be
developed. These trends are illustrated by initiatives such as
the “Critical Path” in the US (2) and the follow-up of the
“EMEA Roadmap to 2010” in Europe (3), although their
impact is as yet hard to predict.
There will be increased pressure to combine (some of)
the regulatory requirements on a global basis. Trends to
harmonise national and international standards, as well as
marketing approval procedures, will continue and have
increasing impact. Globally accepted quality standards may
be developed in the future. However, this will not necessarily
imply a universal quality standard. Quality should be
considered in terms of a modular system, where features
and standards can be added at a national level to a generic
framework.
CHANGES IN EDUCATION TO MEET THE DEMANDS
OF ACADEMIA, INDUSTRY AND REGULATORY
INSTITUTIONS
In order to accommodate projected changes in the
pharmaceutical sciences, the training of the workforce will
be of paramount importance, with signiﬁcant implications
for both undergraduate and graduate teaching and the
development of interdisciplinary education, transnational
and life-long learning programmes. The best educational
programmes will be very different from today, reﬂecting the
rapid changes in and application of new knowledge from
advances in (molecular) biology, materials sciences and
informatics and new ways of teaching and learning based on
advanced information and computer technology. There will
also be a need for strong, socially aware components. Many
academic institutions need to increase their recognition (at
high levels) of the role that drug development plays in their
national economies, and to focus on courses that service this
function. The most successful academic groups will have
critical mass, proven quality (through track record and open,
high quality peer review) and will conduct their communica-
tion in English.
It is questionable whether many Schools of Pharmacy
will adapt their curricula or be able to recruit and retain staff
to meet the diversity of the educational needs in the
pharmaceutical sciences. At the undergraduate level, there
is a concern that the pull towards more clinically based
programmes may be at the expense of underpinning science.
At the graduate level, the primary backgrounds of students
will be more diverse, reﬂecting the need for interdisciplinary
research manifesting as increasing interaction with engineer-
ing, materials science and bioinformatics.
The pedagogic format will continue to move away from
large class lectures and laboratory classes to focus on small
group teaching, problem solving tutorials and computer-
assisted learning. Distance learning, transnational pro-
grammes, peripatetic teaching and virtual universities should
increasingly facilitate the training and continuing professional
development.
There are likely to be speciﬁc shortages in the labour
market. For example, currently, it is difﬁcult to recruit high
level PK-PD modellers. Ways to address this include the
attraction of individuals with engineering backgrounds and
the establishment of distance learning courses that cater both
to deﬁciencies in mathematical skills in many biological
scientists and deﬁciencies in understanding of biology and
the drug development process in those coming from engineer-
ing and statistics backgrounds.
CONCLUSIONS
Signiﬁcant shifts in pharmaceutical research, in pharma-
ceutical business models, and in regulatory approaches are
envisioned by the year 2020.
& Globally operating companies increasingly will buy in
technologies/concepts for new drugs from small pri-
vate enterprises and the academic world. Product
development will be coordinated by these global
players. Major activities will be outsourced to speci-
alized companies and institutions. Quality of the work
and speed will be decisive factors for success.
& Regulatory authorities will be more transparent in
their decision-making process, and global harmoni-
zation will grow.
& Future therapeutic interventions will use new tools
provided by new enabling technologies. The para-
digm of individualized medicine will be accepted as
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standard in many therapeutic ﬁelds, and the border-
lines between diagnostics, drugs and medical devices
will blur.
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